Primary Effusion Lymphoma: Causes, Symptoms & Treatment Options

Introduction

Primary effusion lymphoma (PEL) is a rare and aggressive type of non-Hodgkin lymphoma that primarily affects the serous cavities of the body, including the pleura (the lining of the lungs), pericardium (the lining of the heart), and peritoneum (the lining of the abdomen). First identified in the 1990s, PEL is most commonly associated with individuals who have compromised immune systems, particularly those living with HIV/AIDS. What sets PEL apart from other lymphomas is its tendency to present as fluid accumulation in body cavities rather than forming solid tumors. Due to its rarity and rapid progression, early diagnosis and treatment are critical to improving outcomes for patients.

This article provides a comprehensive overview of Primary Effusion Lymphoma, including its risk factors, symptoms, diagnostic approaches, treatment options, and strategies for managing symptoms at home. By understanding these aspects, patients and their families can make informed decisions about care and treatment.

What is Primary Effusion Lymphoma?

Primary effusion lymphoma is a rare subtype of non-Hodgkin lymphoma that affects the linings of body cavities. It is characterized by specific risk factors, symptoms, diagnostic methods, and treatment strategies, all of which are essential for managing the condition effectively.

Description of Primary Effusion Lymphoma

Primary effusion lymphoma (PEL) is a subtype of B-cell lymphoma that is strongly linked to infection with Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). In many cases, it is also associated with Epstein-Barr virus (EBV). Unlike most other lymphomas, PEL does not typically form solid tumors. Instead, it causes fluid to accumulate in body cavities such as the chest, abdomen, or around the heart. This fluid buildup often leads to significant discomfort and other symptoms, which will be discussed in detail later in this article.

PEL is classified as an aggressive cancer, meaning it progresses rapidly and requires prompt medical attention. Without treatment, the disease can quickly spread to other parts of the body, including the bone marrow and central nervous system. Unfortunately, due to its aggressive nature, PEL often carries a poor prognosis, with survival rates typically ranging from six months to one year after diagnosis. However, early detection and timely treatment can improve outcomes for some patients.

Although PEL is rare, it is most frequently observed in individuals with weakened immune systems, particularly those with HIV/AIDS. The prevalence of PEL is higher in regions where KSHV is more common, such as parts of Africa and the Mediterranean. However, it can occur in individuals from any geographic location.

Risk Factors for Developing Primary Effusion Lymphoma

Lifestyle Risk Factors

Certain lifestyle factors can increase the likelihood of developing Primary Effusion Lymphoma. One of the most significant risk factors is HIV infection, especially in individuals who are not receiving antiretroviral therapy (ART). HIV weakens the immune system, making it more susceptible to infections like KSHV, which is strongly associated with PEL. Additionally, behaviors that increase the risk of contracting HIV, such as unprotected sex or intravenous drug use, may also heighten the risk of developing PEL.

Other lifestyle factors that contribute to a weakened immune system, such as poor nutrition, chronic stress, and limited access to healthcare, can also increase the risk of PEL. Adopting a healthy lifestyle, including proper nutrition and regular medical check-ups, can help reduce the risk of developing this and other immune-related conditions.

Medical Risk Factors

Several medical conditions are linked to an increased risk of developing Primary Effusion Lymphoma. As mentioned earlier, HIV/AIDS is one of the most significant risk factors. Individuals with HIV who are not on effective antiretroviral therapy face a much higher risk of developing PEL due to their compromised immune systems. Additionally, individuals with other conditions that suppress the immune system, such as organ transplant recipients taking immunosuppressive medications, are also at increased risk.

Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is another critical medical risk factor. KSHV is present in nearly all cases of PEL, and individuals infected with this virus are at a higher risk of developing the disease. Co-infection with Epstein-Barr virus (EBV) is also common in PEL patients and may further elevate the risk of developing lymphoma.

Genetic and Age-Related Risk Factors

While Primary Effusion Lymphoma is not typically linked to inherited genetic mutations, certain genetic factors may influence an individual’s susceptibility to viruses like KSHV and EBV, which are associated with PEL. Ongoing research is exploring the genetic factors that may contribute to the development of PEL.

Age is another important risk factor. PEL is most commonly diagnosed in middle-aged to older adults, particularly those with HIV/AIDS. However, it can also occur in younger individuals with compromised immune systems. The average age of diagnosis is typically between 40 and 60 years.

In summary, the risk factors for developing Primary Effusion Lymphoma include a combination of lifestyle, medical, and genetic factors. Individuals with weakened immune systems, particularly those with HIV/AIDS or KSHV infection, are at the highest risk. Understanding these risk factors can help individuals take preventive measures and seek early medical intervention when necessary.

Clinical Manifestations of Primary Effusion Lymphoma

Fever

Fever occurs in approximately 60-70% of patients with Primary Effusion Lymphoma (PEL). It is often triggered by the immune system’s response to lymphoma cells, which release substances that interfere with the body’s temperature regulation. Fever in PEL may be persistent or intermittent and is more common in advanced stages of the disease. It is frequently accompanied by other systemic symptoms such as night sweats and weight loss.

Night Sweats

Night sweats affect about 50-60% of PEL patients. This symptom involves excessive sweating during sleep, often soaking bedclothes and sheets. Night sweats in PEL are thought to result from cytokines—proteins produced by lymphoma cells—that disrupt the body’s temperature regulation. These sweats are typically more common in advanced stages and are often associated with other “B symptoms” like fever and weight loss.

Weight Loss

Unintentional weight loss is reported in about 40-50% of PEL patients. This symptom is often rapid and unexplained, occurring even when the patient maintains a normal diet. Cancerous cells in PEL can increase metabolism, leading to the breakdown of muscle and fat tissue. Additionally, the immune response to lymphoma may suppress appetite and cause malnutrition, further contributing to weight loss. This symptom is often indicative of advanced disease.

Lymphadenopathy

Lymphadenopathy, or swollen lymph nodes, is less common in PEL compared to other lymphomas, occurring in about 20-30% of cases. When present, it is usually due to the spread of lymphoma cells to the lymph nodes. These nodes, which are part of the immune system, can become enlarged when infiltrated by cancerous cells. In PEL, lymphadenopathy is typically seen in later stages and may be accompanied by other systemic symptoms.

Pleural Effusion

Pleural effusion, or fluid accumulation around the lungs, is a hallmark of PEL and occurs in nearly 100% of cases. This fluid buildup results from lymphoma cells infiltrating the pleura, the lining of the lungs. As these cells grow, they cause inflammation and fluid leakage into the pleural space, leading to symptoms such as shortness of breath, cough, and chest pain. Pleural effusion is often one of the first signs of PEL and is a key diagnostic feature.

Ascites

Ascites, or fluid accumulation in the abdomen, occurs in about 80-90% of PEL patients. Similar to pleural effusion, ascites is caused by lymphoma cells infiltrating the abdominal lining, leading to fluid leakage. This can result in symptoms such as abdominal discomfort, bloating, and difficulty breathing. Ascites is often seen in advanced stages of PEL and may require drainage to alleviate symptoms.

Fatigue

Fatigue affects about 70-80% of PEL patients and is often described as persistent tiredness or a lack of energy that does not improve with rest. Fatigue in PEL is likely caused by a combination of factors, including the immune response to cancer, anemia, and the physical toll of the disease. This symptom can significantly impact quality of life and tends to worsen as the disease progresses.

Cough

Cough is reported in about 50-60% of PEL patients, particularly those with pleural effusion. It is usually dry and persistent, caused by fluid buildup in the pleural space, which puts pressure on the lungs. This irritation can lead to coughing, often accompanied by shortness of breath or chest pain. Coughing is frequently one of the first symptoms prompting medical attention.

Chest Pain

Chest pain occurs in about 40-50% of PEL patients, especially those with pleural effusion. The pain is typically sharp and worsens with deep breathing or coughing. It is caused by fluid buildup in the pleural space, which compresses the lungs and surrounding structures. Chest pain may indicate advanced disease and requires prompt evaluation by a healthcare provider.

Abdominal Discomfort

Abdominal discomfort is reported in about 60-70% of PEL patients, particularly those with ascites. It is often described as a feeling of fullness or bloating and may be accompanied by pain. This symptom results from fluid accumulation in the abdomen, which puts pressure on internal organs. In severe cases, it can interfere with eating or breathing. Abdominal discomfort is often a sign of advanced PEL and may require medical intervention to relieve symptoms.

Health Conditions with Similar Symptoms to Primary Effusion Lymphoma

Malignant Pleural Effusion

Malignant pleural effusion occurs when cancer cells invade the pleural space—the area between the lungs and the chest wall—leading to fluid accumulation. This buildup can cause significant breathing difficulties and chest pain. It is most commonly associated with cancers such as lung cancer, breast cancer, or lymphoma.

How to Differentiate Malignant Pleural Effusion from Primary Effusion Lymphoma

Both malignant pleural effusion and primary effusion lymphoma (PEL) can result in fluid accumulation in the chest, causing symptoms like shortness of breath and chest discomfort. However, malignant pleural effusion typically arises from cancers that spread from other parts of the body, such as the lungs or breasts, whereas PEL originates directly in the pleural space as a type of lymphoma.

To distinguish between the two, healthcare providers may use imaging tests like chest X-rays or CT scans to detect fluid buildup. A pleural fluid analysis, where the fluid is examined under a microscope, is crucial for diagnosis. In PEL, the fluid contains lymphoma cells, while in malignant pleural effusion, the cells originate from the primary cancer (e.g., lung or breast cancer). Additionally, PEL is often linked to HIV or immunocompromised states, which are less commonly associated with malignant pleural effusion.

Lymphoma

Lymphoma is a cancer of the lymphatic system, a vital part of the immune system. It is broadly categorized into two main types: Hodgkin lymphoma and non-Hodgkin lymphoma. Lymphoma causes abnormal lymphocyte growth, which can form tumors in lymph nodes or other organs.

How to Differentiate Lymphoma from Primary Effusion Lymphoma

Both lymphoma and primary effusion lymphoma (PEL) are cancers of the lymphatic system and share symptoms such as swollen lymph nodes, fatigue, and unexplained weight loss. However, PEL is unique in that it causes fluid buildup in body cavities (e.g., the chest or abdomen) without forming solid tumors, whereas other types of lymphoma typically present as solid masses in lymph nodes or organs.

To differentiate, a biopsy of the affected tissue or fluid is often performed. In PEL, the biopsy reveals lymphoma cells in the fluid, while other lymphomas show solid tumors in lymph nodes or tissues. Additional diagnostic tools, such as blood tests, imaging studies, and bone marrow biopsies, may also help distinguish PEL from other forms of lymphoma.

Tuberculosis

Tuberculosis (TB) is a bacterial infection caused by Mycobacterium tuberculosis. While it primarily affects the lungs, it can spread to other areas such as lymph nodes, bones, and the brain. TB is highly contagious and spreads through airborne droplets when an infected person coughs or sneezes.

How to Differentiate Tuberculosis from Primary Effusion Lymphoma

Both tuberculosis and primary effusion lymphoma can cause chest pain, shortness of breath, and fluid buildup in the chest. However, TB is an infectious disease, while PEL is a type of cancer. TB often presents with a persistent cough (sometimes producing blood-tinged sputum), fever, night sweats, and weight loss, which overlap with some PEL symptoms.

To differentiate, healthcare providers may order a chest X-ray or CT scan to identify TB-specific signs, such as lung cavities or nodules. A sputum test or pleural fluid analysis can confirm the presence of Mycobacterium tuberculosis, diagnosing TB. In contrast, PEL fluid analysis will show lymphoma cells without evidence of bacterial infection. A TB skin test or blood test can further confirm or rule out tuberculosis.

Sarcoidosis

Sarcoidosis is an inflammatory condition characterized by granulomas—small clusters of immune cells—that form in various organs, most commonly the lungs and lymph nodes. Although its exact cause is unknown, untreated sarcoidosis can lead to significant organ damage over time.

How to Differentiate Sarcoidosis from Primary Effusion Lymphoma

Both sarcoidosis and primary effusion lymphoma can cause shortness of breath, chest pain, and fluid buildup in the chest. However, sarcoidosis often presents with additional symptoms such as a persistent dry cough, skin rashes, and eye inflammation, which are uncommon in PEL.

To distinguish between the two, a chest X-ray or CT scan may reveal granulomas in the lungs, a hallmark of sarcoidosis. A biopsy of affected tissue can confirm the presence of granulomas, while PEL biopsies show lymphoma cells. Blood tests may also detect elevated calcium levels or inflammatory markers in sarcoidosis, which are not typically seen in PEL.

Congestive Heart Failure

Congestive heart failure (CHF) occurs when the heart is unable to pump blood effectively, leading to fluid buildup in the lungs, legs, and other parts of the body. Common symptoms include shortness of breath, fatigue, and swelling in the legs and abdomen.

How to Differentiate Congestive Heart Failure from Primary Effusion Lymphoma

Both congestive heart failure and primary effusion lymphoma can cause fluid buildup in the chest, resulting in shortness of breath and fatigue. However, CHF is often accompanied by swelling in the legs and ankles (edema), rapid weight gain due to fluid retention, and a persistent cough, which are not typical in PEL.

To differentiate, healthcare providers may use an echocardiogram to evaluate heart function. Blood tests measuring brain natriuretic peptide (BNP), a marker of heart failure, can also aid in diagnosing CHF. In contrast, PEL fluid analysis will show lymphoma cells, and imaging tests will not indicate heart dysfunction.

Mesothelioma

Mesothelioma is a rare cancer that affects the lining of the lungs, abdomen, or heart. It is primarily caused by asbestos exposure, a material once widely used in construction. Symptoms include chest pain, shortness of breath, and fluid buildup in the chest or abdomen.

How to Differentiate Mesothelioma from Primary Effusion Lymphoma

Both mesothelioma and primary effusion lymphoma can cause fluid buildup in the chest, leading to shortness of breath and chest pain. However, mesothelioma is often linked to a history of asbestos exposure, while PEL is associated with HIV or immunocompromised states.

To differentiate, a biopsy of the affected tissue or fluid is essential. Mesothelioma biopsies reveal cancer cells originating from the mesothelial lining, while PEL biopsies show lymphoma cells. Imaging tests such as CT or PET scans can further help distinguish the two by identifying the cancer’s location and extent.

Pneumonia

Pneumonia is a lung infection caused by bacteria, viruses, or fungi. It inflames the air sacs in the lungs, which may fill with fluid or pus, leading to symptoms such as cough, fever, shortness of breath, and chest pain.

How to Differentiate Pneumonia from Primary Effusion Lymphoma

Both pneumonia and primary effusion lymphoma can cause shortness of breath, chest pain, and fluid buildup in the chest. However, pneumonia is an infectious disease and often presents with a productive cough (mucus), fever, and chills, which are uncommon in PEL.

To differentiate, healthcare providers may order a chest X-ray or CT scan to detect signs of lung infection, such as areas of consolidation (fluid or pus-filled lung tissue). A sputum test or blood test can identify the infectious organism responsible for pneumonia. In contrast, PEL fluid analysis will reveal lymphoma cells, with no evidence of infection on imaging or laboratory tests.

Improving Primary Effusion Lymphoma: Lifestyle Tips and When to Seek Medical Help

While medical treatments are essential for managing Primary Effusion Lymphoma, incorporating specific lifestyle changes and home remedies can help enhance your overall well-being during treatment:

Rest and Sleep: Prioritize getting enough rest to allow your body to recover from chemotherapy and other lymphoma treatments. Quality sleep is vital for healing and maintaining energy levels.

Hydration: Stay well-hydrated by drinking plenty of fluids. Proper hydration helps flush out toxins, supports bodily functions, and alleviates side effects such as nausea and fatigue.

Balanced Diet: Focus on a nutrient-rich diet that includes a variety of fruits, vegetables, whole grains, and lean proteins. A well-balanced diet can strengthen your immune system and support your body during effusion lymphoma treatment.

Stress Management: Incorporate stress-relief practices like meditation, deep breathing exercises, or yoga into your routine. These techniques can improve your mental and emotional well-being while managing lymphoma symptoms.

Exercise: Engage in gentle physical activities, such as walking, stretching, or light yoga, to boost your energy levels and reduce treatment-related fatigue. Always consult your doctor before starting any new exercise regimen.

Maintaining open and honest communication with your healthcare provider is crucial throughout your treatment journey. Telemedicine offers a convenient way to stay connected with your doctor, enabling you to discuss symptoms, treatment progress, and any concerns from the comfort of your home.

Living with Primary Effusion Lymphoma: Tips for a Better Quality of Life

Living with Primary Effusion Lymphoma can be challenging, but taking proactive steps can help you maintain a better quality of life:

Stay Informed: Educate yourself about the causes of Primary Effusion Lymphoma, its symptoms, and the available treatment options. Being informed can empower you to make confident decisions about your care.

Build a Support System: Surround yourself with a network of supportive family members, friends, or peers in support groups. Sharing your experiences and feelings can help you navigate the emotional and physical challenges of living with effusion lymphoma.

Follow Your Treatment Plan: Adhere to your prescribed medications and therapies as directed by your healthcare team. Consistency in following your treatment plan is key to effectively managing lymphoma symptoms and improving outcomes.

Communicate with Your Healthcare Team: Keep your doctor informed about any changes in your symptoms or side effects. Open communication ensures that your lymphoma treatment remains effective and tailored to your evolving needs.

Practice Self-Care: Dedicate time to activities that bring you joy, whether it’s reading, listening to music, or pursuing a hobby. Prioritizing self-care can reduce stress and enhance your emotional well-being as you manage Primary Effusion Lymphoma.

Conclusion

Primary Effusion Lymphoma is a rare and aggressive form of cancer that requires timely diagnosis and treatment. Early intervention with chemotherapy, targeted therapies, and supportive care can significantly improve both outcomes and quality of life. If you or a loved one has been diagnosed with Primary Effusion Lymphoma, seeking medical attention promptly is essential to exploring the best treatment options available.

Our telemedicine practice offers a convenient and accessible way to connect with healthcare professionals from the comfort of your home. Reach out to us for personalized care, guidance, and support as you navigate your journey with Primary Effusion Lymphoma.

James Kingsley

Learn More